Letters, Statements and Analysis

Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve.














AMCP submits letter to West Virginia Speaker of Delegates on House Bill 4524 and Establishing Guidelines for the Substitution of Certain Biologic Pharmaceuticals by Pharmacists.   

AMCP submits letter to Vermont House Committee on Health Care regarding Senate Bill 92 on Substitution of Interchangeable Biologic Products.   

AMCP submits letter to New Hampshire Senate Health and Human Services Committee on Senate Bill 350 regarding Interchangeable Biologic Products Dispensed by Pharmacists.   

AMCP submits letter to Connecticut Senate General Law Committee on Senate Bill 197 regarding Interchangeable Biologic Products.    


AMCP submits letter to Wyoming Joint Labor, Health and Social Services Committee on Senate File 75 and Authorizing Pharmacists to Dispense Interchangeable Biologic Products.   

AMCP Submits Letter to Alaska House Finance Committee regarding Senate Bill 32 and the regulation of Biologic Product Substitutions.   


AMCP joins 11 organizations in letter to the OIG in support of establishing a safe harbor provision that would encourage the development of additional value-based contracts for the Medicare and Medicaid populations.   


AMCP Submits Letter to Speaker of Wisconsin Assembly regarding Assembly Bill 679 and the Regulations on Pharmacists Substituting Biological Products   


AMCP joins other stakeholders in support of the CREATES Act   



AMCP Delivers Remarks at FDA Opioid Policy Steering Committee Meeting on How the FDA Can Help Address the Opioid Epidemic   


AMCP Submits Letter to Energy & Commerce Subcommittee on Health in Support of HR 2026 – The Pharmaceutical Information Exchange (PIE) Act   

AMCP sends letter to Michigan House Health Policy Committee citing concerns with HB 4472 and regulations on pharmacists substituting interchangeable biological products   


AMCP Submits Comments to CMS on Medicare Advantage and Medicare Part D Proposed Rule   

Content for class "break" Goes Here